GSA Capital Partners LLP Has $922000 Position in Enanta Pharmaceuticals Inc (ENTA)

Lloyd Doyle
January 19, 2018

The company has a consensus rating of "Hold" and a consensus target price of $45.25. The stock increased 1.01% or $3.39 during the last trading session, reaching $339.6. About 110,227 shares traded or 1.21% up from the average.

TRADEMARK VIOLATION WARNING: "Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price" was published by The Lincolnian Online and is owned by of The Lincolnian Online. Jacobs Levy Equity Management invested in 0% or 31,703 shares. New Oriental Ed & Tech Grp I now has $16.44 billion valuation. The stock increased 2.92% or $1.78 during the last trading session, reaching $62.76. About 1.12 million shares traded. Campbell & CO Investment Adviser LLC bought a new stake in Enanta Pharmaceuticals in the third quarter valued at $220,000. PolarityTE, Inc. (NASDAQ:COOL) has risen 140.86% since January 17, 2017 and is uptrending. It has outperformed by 28.35% the S&P500. Zacks Investment Research downgraded Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, October 4th. Therefore 61% are positive. JMP Securities raised their price target on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Citigroup Inc invested in 24,482 shares or 0% of the stock. (NYSE:EDU) has "Neutral" rating given on Thursday, July 21 by Nomura. The company was reinitiated on Friday, July 8 by Jefferies. The firm earned "Buy" rating on Friday, February 17 by Deutsche Bank. JP Morgan upgraded New Oriental Education & Technology Group Inc. The firm has "Equal-Weight" rating given on Wednesday, October 18 by Barclays Capital. Morgan Stanley initiated the stock with "Overweight" rating in Thursday, April 14 report. It also upped Schein Henry Inc Com (NASDAQ:HSIC) stake by 19,019 shares and now owns 38,488 shares. Taiwan Semiconductor Mfg Ltd (NYSE:TSM) was reduced too. Legal And General Grp Public Ltd Co holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. Therefore 40% are positive. Ellington Grp Limited Liability Company invested 0.04% of its portfolio in Enanta Pharmaceuticals, Inc. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The rating was maintained by RBC Capital Markets on Friday, October 20 with "Buy". The stock has "Hold" rating by Robert W. Baird on Monday, November 20. First Manhattan Co. now owns 947,100 shares of the biotechnology company's stock worth $44,324,000 after buying an additional 12,400 shares in the last quarter. Kempner Capital Management Inc sold 11,659 shares as the company's stock rose 4.66% with the market. JP Morgan has "Overweight" rating and $26 target. On Friday, October 20 the stock rating was maintained by Robert W. Baird with "Hold".

Investors sentiment increased to 1.6 in 2017 Q3. Its up 0.75, from 0.85 in 2017Q2. It increased, as 9 investors sold ENTA shares while 31 reduced holdings. Weiss Multi holds 30,000 shares. Armistice Capital Llc who had been investing in Enanta Pharmaceuticals Inc for a number of months, seems to be less bullish one the $1.20 billion market cap company.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 20th. Wells Fargo & Mn reported 51,232 shares. The institutional investor owned 56,419 shares of the biotechnology company's stock after buying an additional 2,803 shares during the quarter.

Moreover, California State Teachers Retirement Sys has 0% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Aqr Capital Management Ltd Liability Co invested in 157,993 shares or 0.01% of the stock. Vanguard Group Inc. grew its position in shares of Enanta Pharmaceuticals by 6.9% during the second quarter. (NASDAQ:ENTA) for 76,409 shares. Proshare Advsr Ltd Liability reported 0% stake. Sg Americas Secs Limited Liability Corp stated it has 5,662 shares. Thrivent For Lutherans holds 0% or 8,730 shares in its portfolio. Alphamark Advisors Llc who had been investing in Enanta Pharmaceutical for a number of months, seems to be less bullish one the $1.17B market cap company. (NASDAQ:ENTA) to report $0.04 EPS on February, 14.They anticipate $0.30 EPS change or 115.38% from last quarter's $-0.26 EPS. During the same quarter past year, the business earned ($0.09) earnings per share. ENTA's profit would be $765,309 giving it 402.13 P/E if the $0.04 EPS is correct. After having $1.86 EPS previously, Enanta Pharmaceuticals, Inc.'s analysts see -97.85% EPS growth. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. The company??s research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a 72.08 P/E ratio. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article